Description
For more than 30 years, the Medical Technology Stock Letter (MTSL) has provided independent investment advice based on rigorous analysis of emerging biotechnology companies and a unique perspective on industry fundamentals. MTSL has a proven track record of identifying many of today’s industry leaders well before the consensus of other analysts. The Letter also offers detailed information in layman’s terms to allow the subscriber to make timely, educated investment decisions.
**You may cancel within 48 hours of your subscription date for a full refund. The contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Nothing herein should be construed as an offer to buy or sell any security. The publisher and its associates, directors or employees may have positions in, and may from time to time make purchases or sales of, securities mentioned herein. We cannot guarantee and you should not assume that future recommendations will equal the performance of past recommendations or be profitable.
Reviews
There are no reviews yet.